These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 7743614)

  • 21. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
    Waters D; Higginson L; Gladstone P; Kimball B; Le May M; Boccuzzi SJ; Lespérance J
    Circulation; 1994 Mar; 89(3):959-68. PubMed ID: 8124836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.
    Flaker GC; Warnica JW; Sacks FM; Moyé LA; Davis BR; Rouleau JL; Webel RR; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1999 Jul; 34(1):106-12. PubMed ID: 10399998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.
    MacMahon S; Sharpe N; Gamble G; Hart H; Scott J; Simes J; White H
    Circulation; 1998 May; 97(18):1784-90. PubMed ID: 9603532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania P; Stone PH; Bairey Merz CN; Cosin-Aguilar J; Koylan N; Luo D; Ouyang P; Piotrowicz R; Schenck-Gustafsson K; Sellier P; Stein JH; Thompson PL; Tzivoni D
    Circulation; 2007 Feb; 115(6):700-7. PubMed ID: 17283260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
    Wassmann S; Faul A; Hennen B; Scheller B; Böhm M; Nickenig G
    Circ Res; 2003 Oct; 93(9):e98-103. PubMed ID: 14551237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventing angiographic progression of coronary atherosclerosis with pravastatin.
    Daida H; Ouchi Y; Saito Y; Yamada N; Nishide T; Mokuno H; Kurata T; Sato H; Eto M; Ako JY; Tango T; Yamaguchi H;
    J Atheroscler Thromb; 2003; 10(1):25-31. PubMed ID: 12621161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
    Sacks FM; Pasternak RC; Gibson CM; Rosner B; Stone PH
    Lancet; 1994 Oct; 344(8931):1182-6. PubMed ID: 7934538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group.
    Tamura A; Mikuriya Y; Nasu M
    Am J Cardiol; 1997 Apr; 79(7):893-6. PubMed ID: 9104901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study).
    Nakamura Y; Yamaoka O; Uchida K; Morigami N; Sugimoto Y; Fujita T; Inoue T; Fuchi T; Hachisuka M; Ueshima H; Shimakawa H; Kinoshita M
    Cardiovasc Drugs Ther; 1996 Sep; 10(4):475-83. PubMed ID: 8924063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome.
    Crouse JR; Byington RP; Bond MG; Espeland MA; Sprinkle JW; McGovern M; Furberg CD
    Control Clin Trials; 1992 Dec; 13(6):495-506. PubMed ID: 1334821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-lowering for prevention of coronary heart disease: what policy now?
    Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
    Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
    Bestehorn HP; Rensing UF; Roskamm H; Betz P; Benesch L; Schemeitat K; Blümchen G; Claus J; Mathes P; Kappenberger L; Wieland H; Neiss A
    Eur Heart J; 1997 Feb; 18(2):226-34. PubMed ID: 9043838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
    J Atheroscler Thromb; 1996; 3(2):95-104. PubMed ID: 9226461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients.
    Am J Cardiol; 1993 Nov; 72(14):1031-7. PubMed ID: 8213583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
    Kuivenhoven JA; Jukema JW; Zwinderman AH; de Knijff P; McPherson R; Bruschke AV; Lie KI; Kastelein JJ
    N Engl J Med; 1998 Jan; 338(2):86-93. PubMed ID: 9420339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.